Fortune India presents award to Ajanta Pharma

MUMBAI, India - Aug. 24, 2015 - PRLog -- Fortune India presents award to Ajanta Pharma

(3^rd Largest Wealth Creator in 5 year CAGR 93.14% in Mid-Size Companies)

Mumbai – (August 24^th, 2015) – Fortune India has published list of 500 mid-size companies and ranked them on various parameters based on the results of 2013-14.  Ajanta Pharma features very prominently in the lists.  Ajanta’s ranking on various parameters is given below:

   ·         Ranked 3^rd largest Wealth Creator on 5 year CAGR  93.14%

   ·         Ranked 10^th on Return on Capital Employed (ROCE)

   ·         Ranked 21^st in Net Profit

   ·         Ranked 182^nd in Sales

On 17^th August 2015, Fortune India organized an award function to present the awards to Top 10 largest wealth creator companies and Ajanta is one of those elite companies.

The awards were presented by Mr. Piyush Goyal, Minister of State – Power, Coal, New & Renewable Energy, Govt. of India to Mr. Yogesh Agrawal, Managing Director and Mr. Rajesh Agrawal, Jt. Managing Director of the company.

About Ajanta Pharma Limited

Ajanta Pharma is an leading speciality generic company with clear focus on fast growing therapeutic segments of Cardiology, Opthalmology, Dermatology, Anti-malarials & Pain Management and is among the fastest growing in the country.  Many of company’s products are first in the market place and are leading in their sub therapeutic segments.

In the Emerging Markets company has presence in more than 35 countries in Africa, Asia, Middle East, CIS and Latin America. For each of these markets company has customised product basket with wider therapeutics presence.  The company is now building a portfolio of ANDAs for the regulated markets of USA and has entered this market with its maiden product.

Company’s state of the art R&D centre for formulation development is located at Mumbai, having a team of 500+ people.  Company has world class manufacturing facilities - 5 located in India and 1 at Mauritius.  One of the manufacturing facilities in India is approved by US FDA, UK MHRA, pre-qualification from WHO, apart from having approval from FDAs of many other countries.  The Recently completed new formulation manufacturing facility (oral solids) at Dahej is undergoing qualification and will be dedicated for Regulated Markets.

For more details on the company please visit our website www.ajantapharma.com